Constellation Energy's Stock Slide Highlights Regulatory and Guidance Risks, Affirming Cautious Investment Stance

What happened

Constellation Energy's stock has declined 28% from its 52-week high, with recent news attributing this to regulatory uncertainty and EPS guidance below analysts' expectations. This aligns with the DeepValue master report's warning that FERC/PJM co-location rules could impose minimum charges, threatening profits from datacenter contracts in key markets like PJM. The weak EPS guidance underscores management's struggle to convert AI-driven demand into reliable earnings, despite a crowded market narrative around its nuclear and Calpine assets. The report emphasizes that CEG's valuation at ~$326 per share is demanding, with a 44x P/E multiple pricing in substantial growth without disclosed datacenter backlog metrics. Thus, the investment case now hinges on near-term catalysts: the March 31, 2026 guidance call and regulatory clarity, which will test whether the company can deliver on its promises.

Implication

The stock's decline signals fragile sentiment, where regulatory and earnings risks outweigh growth optimism, necessitating a defensive stance. High valuation at 44x P/E leaves minimal margin for error, making any guidance disappointment or regulatory setback potentially punitive for equity holders. According to the DeepValue report, the 'WAIT' rating is justified as the next 3-6 months offer critical checkpoints on contract cadence and FERC/PJM rule impacts, which could compress premiums. Investors must scrutinize the upcoming March 31 guidance call for quantified datacenter MW bookings and earnings power, rather than relying on promotional announcements. Until then, holding off or considering entry only at lower prices, such as the report's $280 attractive level, reduces exposure to unproven narratives.

Thesis delta

The news article does not alter the core thesis from the DeepValue report, which already advocates waiting for quantified guidance and datacenter MW bookings before investing. However, it reinforces that regulatory and earnings risks are materializing, increasing the urgency for CEG to deliver on its catalysts to sustain confidence. Thus, the thesis remains unchanged: avoid new capital until concrete evidence emerges from the March 31 event and regulatory rulemaking.